Dual-acting β2 agonists/muscarinic antagonists

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 9, 2006, Pages 1327-1331

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

Bronchodilator; COPD; Muscarinic antagonists 2 agonist

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FORSKOLIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXOTREMORINE; SALBUTAMOL; SALMETEROL; STEROID; UNCLASSIFIED DRUG; YM 46303;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BIOLOGICAL ACTIVITY; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG COST; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; PATENT; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

EID: 33748682942     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.9.1327     Document Type: Article

References (5)

1. KAIK G: Combined administration of ipratropium bromide (sch 1000) and fenoterol in patients with chronic obstructive airway disease. Wien. Klin. Wochenschr. (1975) 87(19):653-656.
2. CHRISCHILLES E, GILDEN D, KUBISIAK J et al.; Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers. Am. J. Manag. Care. (2002) 8(10):902-911.
3. FRIEDMAN M, SERBY CW MENJOGE SS et al.: Pharmacoeconomic evaluation of a combination of ipratropium, plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest (1999) 115(3):635-641.
4. DAVIS L: News roundup. Biopartnering Today Spring (2005) 4
5. GlaxoSmithKline GlaxoSmithKline and Theravance to form strategic alliance (2004) Press release.